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Abstract
A randomized trial allows estimation of the causal effect of an intervention
compared to a control in the overall population and in subpopulations defined
by baseline characteristics. Often, however, clinical questions also arise regard-
ing the treatment effect in subpopulations of patients, which would experience
clinical or disease related events post-randomization. Events that occur after
treatment initiation and potentially affect the interpretation or the existence of
the measurements are called intercurrent events in the ICH E9(R1) guideline. If
the intercurrent event is a consequence of treatment, randomization alone is no
longer sufficient to meaningfully estimate the treatment effect. Analyses compar-
ing the subgroups of patients without the intercurrent events for intervention and
control will not estimate a causal effect. This is well known, but post-hoc anal-
yses of this kind are commonly performed in drug development. An alternative
approach is the principal stratum strategy, which classifies subjects according to
their potential occurrence of an intercurrent event on both study arms. We il-
lustrate with examples that questions formulated through principal strata occur
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naturally in drug development and argue that approaching these questions with
the ICH E9(R1) estimand framework has the potential to lead to more transparent
assumptions as well as more adequate analyses and conclusions. In addition, we
provide an overview of assumptions required for estimation of effects in principal
strata. Most of these assumptions are unverifiable and should hence be based on
solid scientific understanding. Sensitivity analyses are needed to assess robustness
of conclusions.
Keywords: Causal Inference; Counterfactuals; Estimand; Intercurrent Event; Potential
Outcomes.
1 Introduction
One main concept of the E9(R1) guideline [1] by the International Conference of Har-
monization (ICH) is the notion of intercurrent events, defined as “... Events occurring
after treatment initiation that affect either the interpretation or the existence of the
measurements associated with the clinical question of interest. ...”. The ICH E9(R1)
guideline outlines five strategies to acknowledge intercurrent events as part of the treat-
ment effect/estimand of interest. The treatment policy strategy effectively makes the
intercurrent event part of the treatment investigated. The composite and while-on-
treatment strategies modify the variable/endpoint of interest to reflect the intercurrent
event. The hypothetical strategy envisages a hypothetical scenario in which the inter-
current event does not occur. Finally, the principal stratum strategy, based on ideas
introduced by [2], defines a subpopulation of interest according to the potential occur-
rence of an intercurrent event on one or all treatments.
As part of a principal stratum strategy, the subpopulation of interest could for example
be subjects who would tolerate treatment if assigned to the test treatment. In this case
subpopulation membership on the test arm would be known. On the control arm how-
ever subpopulation membership is not observed and hence not known with certainty.
Alternatively, the subpopulation of interest could be the patients who would tolerate
both test and control treatment.
The principal stratum strategy has not been commonly used in clinical trials so far and
is not uncontested, see [3, 4] or the discussion initiated earlier by [5]. First, it relates
to a subpopulation of the overall trial population that is not identifiable with certainty.
This may be perceived to render the obtained treatment effect estimate of limited in-
terest from a direct practical perspective. Second, a principal stratum estimand relates
to a question where one cannot rely on randomization anymore to ensure comparable
baseline populations across treatment groups in the subpopulation of interest. Strong
assumptions are typically needed to estimate this estimand. In the ICH E9(R1) guide-
line it is specifically mentioned that a run-in period may be an effective design feature
to robustly identify a target population defined by a specific clinical event (and thus
estimate a principal stratum effect). The use of these designs might however be limited
to special situations.
For these reasons, one might be tempted to generally challenge the relevance of the
principal stratum strategy in drug development.
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In this paper we would like to illustrate with examples that many relevant scientific ques-
tions in drug development can be addressed with the principal stratum strategy. Often,
these questions do not correspond to the primary endpoint in the specific trial, but they
increase the scientific understanding of the treatment effect in relevant subpopulations,
and may impact approval decisions and labeling.
The outline of this paper is as follows. In Section 2 we will provide a review of potential
outcomes and principal stratum estimands. In Section 3 we review examples from drug
development practice, where the question of interest can be framed to be of principal
stratum type. Section 4 then reviews analysis methods and assumptions citing existing
literature and outlines a R [6] implementation. The paper ends with a discussion in
Section 5.
2 Introduction to Potential Outcomes and Principal
Stratum Estimands
The term principal stratum was first introduced by [2] (see also [7] for a rather recent
review on principal stratification) and originates from the causal inference literature
under the potential outcome approach (see [8, 9] for introductions). In this section we
will introduce potential outcomes, a central idea of causal inference, which are important
to formulate principal stratum estimands. Note that the other estimand strategies
in the ICH E9(R1) guideline can also be formulated using potential outcomes [10].
We illustrate potential outcomes with an example: Let Z be the binary indicator for
treatment (Z = 1 corresponding to the test treatment and Z = 0 corresponding to
control) and Y be the outcome of interest. Assume a treating physician is deciding on
the treatment to prescribe. Ideally she would make that decision based on knowledge
on what the outcome for the patient would be if given the test treatment, Y (Z = 0),
abbreviated as Y (0), and what the outcome would be under treatment, Y (Z = 1) =
Y (1). In reality of course, neither Y (0) and Y (1) is known when assigning a treatment,
and even after observation, for a given patient, only one of the potential outcomes
Y (0) or Y (1) can be observed. So, even after observation of Y one cannot be sure if
the correct decision was made for this particular patient: Individual causal effects, i.e.
Y (1)−Y (0), are not observed. On a population level, however, such “causal” statements
can be made. One then targets the average causal effect E(Y (1) − Y (0)), where the
expectation is taken with respect to the population of interest.
Statistical estimation of E(Y (1)− Y (0)) in a randomized trial can be performed based
on the fact that treatment assignment is independent of any patient characteristic, so
that Y (1) and Y (0) are independent of Z implying that
E(Y (1)− Y (0)) = E(Y (1))− E(Y (0))
= E(Y (1)|Z = 1)− E(Y (0)|Z = 0)
= E(Y |Z = 1)− E(Y |Z = 0).
This means we can estimate the average causal effect by the difference in averages on the
two arms, as the population of patients is comparable across the two treatment arms.
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In an observational study the treatment decision between Z = 0 and Z = 1 might depend
on further measured or unmeasured patient characteristics X, so that the patients who
receive Z = 1 (for whom we observe Y (1)) might be systematically different from those
patients who receive Z = 0 (for whom we observe Y (0)), so that Y (1) and Y (0) are not
independent of Z. In this case E(Y |Z = 1)− E(Y |Z = 0) 6= E(Y (1)− Y (0)), because
E(Y (1)) 6= E(Y (1)|Z = 1) and E(Y (0)) 6= E(Y (0)|Z = 0): The patients receiving
Z = 0 are not representative of the overall population and similarly those receiving
Z = 1 are not representative of the overall population. The value of potential outcomes
from a notational perspective is that they allow to decouple the outcome Y from the
actual treatment Z received.
Denoting by Y (1)i the potential outcome for a patient i and by S a population of
patients, causal treatment effects are defined as a comparison of potential outcomes
{Y (1)i, i ∈ S} versus {Y (0)i, i ∈ S} on a common set of units S. A comparison of
{Y (1)i, i ∈ S1} versus {Y (0)i, i ∈ S2} with S1 6= S2 is not a causal effect [11]. A causal
effect can thus be conceptualized as a comparison of outcomes “had everyone received
treatment” versus outcomes “had everyone received control”, see also Figure 1. This
focus on causal effects is also present in the ICH E9(R1) guideline [1, Section A.3],
where estimands are introduced as “... Central questions for drug development and
licensing are to establish the existence, and to estimate the magnitude, of treatment
effects: how the outcome of treatment compares to what would have happened to the
same subjects under alternative treatment (i.e. had they not received the treatment, or
had they received a different treatment). ...”.
To illustrate a main motivation of the principal stratum strategy we will consider a sim-
ple, generic example. Assume a randomized two-arm trial is planned, with an outcome
Y assessed at week 12. Now assume that one is interested in the treatment effect in
those patients that experience a specific post-randomization event of interest. Denote
by S = 1 occurrence and by S = 0 absence of the post-randomization event. A naive
Association Causation
E(Y|Z=1) E(Y|Z=0)vs E(Y(1)) vs E(Y(0))
Z=1
Z=0
Overall population
Figure 1: Difference between association and causation (adapted based on [8, Figure
1.1])
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S(0) = 1 S(0) = 0
S(1) = 1 {S(1) = 1} ∩ {S(0) = 1} {S(1) = 1} ∩ {S(0) = 0}
S(1) = 0 {S(1) = 0} ∩ {S(0) = 1} {S(1) = 0} ∩ {S(0) = 0}
Table 1: Principal strata defined by the potential outcomes S(0) and S(1).
analysis that might be employed in such situations is to subset the overall trial data
to patients with S = 1 on both test and control arm and then perform the analysis of
interest. The variable S is a post-randomization variable and an outcome influenced
by treatment, i.e. S depends on Z. This means for patients on the intervention arm
we observe the potential outcome S(Z = 1) and on control we observe the potential
outcome S(Z = 0). From this perspective the population of patients with S(1) = 1
and S(0) = 1 might be quite different. The naive analysis mentioned above is hence
“breaking the randomization”, as the patient populations on the compared arms can be
different, and one is not comparing “like with like”, and thus not estimating a causal
effect. If we would numerically observe a treatment effect in such an analysis, we would
not be sure whether the difference in outcome is due to the difference in treatment, or
due to the difference in the compared populations.
The idea of principal stratum estimands is to stratify patients based on their potential
outcomes S(0), S(1) for all treatments. In the case of a binary post-randomization
event S and two treatments one can hence define four strata based on both potential
outcomes, see Table 1. Every patient falls into one particular of the four strata. Causal
interpretations are made possible by the fact that membership to a principal stratum is
not affected by treatment assignment.
In the described setting, patients that would experience the event under either treatment
would have S(1) = 1 and S(0) = 1 (i.e. the top-left cell in Table 1). Alternatively of
interest could be those patients that experience the event under treatment S(1) = 1,
which is the union of the two cells {S(1) = 1}∩{S(0) = 1} and {S(1) = 1}∩{S(0) = 0}
in Table 1.
Contrary to the naive analysis this stratification leads to a causal effect: We now stratify
the population according to the same rule on treatment and control arm. The actual
identification of the subpopulation corresponding to the stratum/strata of interest is gen-
erally not possible, not even after observing the outcome Y and the post-randomization
event S in a given trial. For patients on the intervention arm we observe S(1), but not
S(0), and vice versa for patients on the control arm.
Based on our experience (see also the examples in Section 3) one is often interested in
the group of patients that experience the post-randomization event under one treatment
(union of two principal strata, or a row in Table 1), for example the stratum with
S(1) = 1. Then in one arm patients in the stratum can be identified, but not on the
other arm. Generally, assumptions are required for estimation of the treatment effect
in the stratum/strata of interest. One could argue that the naive analysis (that subsets
based on the observed S on both treatment arms) is estimating the treatment effect in
the principal stratum {S(1) = 1} ∩ {S(0) = 1} under the assumption that S(1) = S(0),
i.e. occurrence of the post-randomization event is not treatment related. Viewing
this naive analysis within potential outcome notation reveals the implicit assumption
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underlying the analysis, which might often be quite strong and rarely justified.
While often one is primarily interested only in a subset of the overall trial population
(one principal stratum or a union of strata), it is good practice to evaluate and report
results also for the complementary group(s) or all strata (or union of strata) if the model
allows to extract that information.
A complication arises when the outcome Y is not a measurement assessed at a specific
timepoint, but of time-to-event type, such as death for overall survival (OS). In this
situation the event itself can constitute a competing risk for occurrence of the intercur-
rent event (i.e. after observing the main event of interest, patients would no longer be
at risk for experiencing the intercurrent event). In these situations particular care is
needed to define the principal stratum of interest as well as the analysis strategy. Naive
analyses conditioning on observed intercurrent event occurrence in this situation would
then not only compare non-randomized populations but may also suffer from immortal
bias, as patients for which we observe the intercurrent event are “immortal” until that
timepoint.
In the causal inference literature the principal stratum approach has been controversially
discussed in particular with respect to its relationship to mediation analysis, see for
example [5]. In the latter, one tries to disentangle the overall effect via direct and
indirect effects (mediated via the intercurrent event or not). In the language of the ICH
E9(R1), mediation analysis can be interpreted as targeting a hypothetical estimand.
In many situations where a principal stratum estimand is of interest also an estimand
derived from a mediation analysis could be of interest. However, the two approaches
answer different questions and it depends on the specific setting which might be of more
interest. See also the comparisons between principal stratum and mediation approaches
in [12] on a conceptual level, and [13] on a practical example. In this paper, we will focus
on principal stratum estimands, not the least because this concept has been proposed
as one of five strategies to address intercurrent events in the ICH E9(R1) guideline.
3 Examples
In this section we discuss scientific questions of interest in drug development that are
formulated as principal stratum estimands. For a discussion how to position these ques-
tions in the broader drug development landscape we refer to Section 5. In this section
we will not discuss analysis strategies or assumptions that would allow estimation. We
return to this aspect in Section 4. Table 2 gives an overview of the examples.
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3.1 Multiple sclerosis
Multiple sclerosis (MS) is an auto-immune disease of the central nervous system char-
acterized by relapses, with varying symptoms, for example visual deficits, cognitive
and motor impairment. Multiple sclerosis typically starts out with a phase where pa-
tients have relapses, but fully recover after the relapses (relapsing remitting form of
MS, RRMS). Then the disease transitions to a phase where patients have a continuous
disease progression where relapses are less common, and patients often do not fully re-
cover from these, leading to increased disability (secondary progressive MS, SPMS). The
typical primary endpoint in RCTs for SPMS is time to confirmed disability progression.
In Magnusson et al. [14] EXPAND (NCT01665144, [15]), a large placebo-controlled
trial of siponimod in patients with SPMS, is discussed. The primary objective of the
trial was to show efficacy of siponimod versus placebo in terms of time to confirmed
disability progression. The endpoint was achieved, but the question was raised whether
a treatment effect would also be present in patients that would not experience relapses.
As siponimod is known to prevent relapses this is a non-trivial question to answer.
In this setting the intercurrent event S is post-randomization relapse, and [14] consid-
ered estimation of the treatment effect in patients that would not relapse under both
siponimod and placebo, i.e. in the stratum {S(0) = 0} ∩ {S(1) = 0}. The probability
of disability progression was assessed at a specific timepoint, so that the outcome Y is
binary. The estimand of interest here was taken as the risk ratio
RR :=
E(Y (1)|S(1) = 0, S(0) = 0)
E(Y (0)|S(1) = 0, S(0) = 0) .
3.2 Treatment effect in early responders
Biomarkers or early readouts can be useful to investigate whether an investigational
medicine works as intended on a biological level. In some situations, it is realistic
to assume that patients, whose post-randomization short term biomarker levels indicate
that they do not sufficiently respond to the drug, are also unlikely to respond on clinically
relevant long term outcomes, such as time-to-event.
One recent example is in the cardiovascular area. Inflammation has been identified as
playing a key role in atherosclerosis and cardiovascular disease. The CANTOS out-
comes trial in prevention of cardiovascular events (NCT01327846, [16]) investigated
treatment with canakinumab, an anti-inflammatory agent, against placebo, both on top
of standard of care. The primary outcome was the time to major adverse cardiovascu-
lar event (MACE) and significant. In this specific case the biomarker of interest is a
downstream inflammatory marker, high sensitivity c-reactive protein (hs-CRP), where
lower values indicate less inflammation. Interest here was in determination of the treat-
ment effect for patients that, three months after start of treatment with canakinumab,
were able to lower hs-CRP below a specific target level. As the mechanism of action
of canakinumab is lowering inflammation, one would suspect that patients who do not
achieve the biomarker threshold also have a lower benefit in terms of the time-to-event
outcome. Vice versa, patients that achieve the threshold have a larger treatment effect.
Another example is in oncology, where tumor size shrinkage is a measurement that can
be assessed early. Again, for patients with a lack of tumor shrinkage it is less likely that
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those benefit from the treatment on longer term survival outcomes. In pharmacometrics
so-called tumor growth inhibition (TGI) metrics have gained popularity. Such models are
drug-independent and attempt to link tumor response and baseline prognostic factors
to a time-to-event endpoint such as OS. In these models, tumor response is quantified
by extracting a summary statistics from a longitudinal model of tumor size. The goal of
these TGI analyses is to “predict” OS survival functions and induced effects of treatment
based on such summary statistics (see for example [17]). Again, one could consider the
treatment effect (in terms of OS) in patients that achieve a specific favorable tumor
metric shortly after treatment start.
Determining the potential long-term treatment effect for a patient based on a short-term
read-out, such as e.g. hs-CRP or TGI, can be useful information: It might support the
decision on treatment modifications after treatment start.
Let S denote the event of achieving an early readout value (i.e. hs-CRP or TGI) either
(1) lower than a target level or (2) achieving a certain percent decrease with respect to
the patient’s baseline value, at a short time t˜ after start of treatment.
Interest focuses on comparing Y (1) and Y (0) in the stratum of patients with S(1) = 1,
and contrasting this for example to the results for patients with S(1) = 0. Depending on
the questions one could also be interested in the subpopulation of patients with S(0) = 1
and contrast results to those with S(0) = 0. Effect measures of interest can be based
on the survival functions
U1(t) := P (Y (1) > t|S(1) = 1) and U0(t) := P (Y (0) > t|S(1) = 1),
e.g. event probabilities at a time t∗ > t˜:
δ(t∗) = U1(t∗)− U0(t∗)
or a time-averaged version
∫ t∗
0
δ(t)dt = E[min(Y (1), t∗) −min(Y (0), t∗)], the difference
in restricted mean survival times [18].
An important point to consider in these situations (as discussed in [19]) is that response
on the early read-out might simply act as a marker for prognostically favorable patients
and thus not modify the treatment difference versus the control treatment itself. For
example comparing Y (1) for patients with S(1) = 1 versus those with S(1) = 0 does
not allow for a statement on the treatment effect (which is a contrast involving Y (1)
and Y (0)).
Another challenge is that, depending on the time point t˜ of the measurement of the
post-randomization marker, some events related to Y might already have happened.
We discuss this general point later in Section 4.7.
3.3 Antidrug antibodies for targeted oncology drugs
In oncology, an increasing number of targeted anticancer agents and immunotherapies
are of biological origin [20]. These biological drugs may trigger immune responses that
lead to the formation of antidrug antibodies (ADAs). ADAs may be directed against
immunogenic parts of the drug and may affect its efficacy or safety, or they may bind to
regions of the protein which do not affect safety or efficacy, with little to no clinical effect
[21]. ADA positivity (ADA+) is triggered by treatment, appears post-randomization
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and has the potential to affect the interpretation of the outcome. It can thus be con-
sidered an intercurrent event in the language of the ICH E9(R1) guideline. Note that
in an RCT it can well be that a biologic drug is only administered in the test but not
the control arm, i.e. by construction ADAs can only form in the intervention arm. To
make things concrete, assume that our outcome of interest Y is again a time-to-event
endpoint, e.g. OS. The intercurrent event S is occurrence of an ADA at a fixed milestone
time point t˜ after randomization, e.g. t˜ = 3 weeks.
A relevant clinical question for the intercurrent event of ADA-positivity is whether
ADA+ patients still benefit from the drug.
One way to answer the above clinical questions is to assess the effect of the randomized
treatment in those patients that would be ADA+ under treatment, i.e. we are interested
in the treatment effect in the stratum {S(1) = 1}. This is the union of the two strata
{S(1) = 1} ∩ {S(0) = 1} and {S(1) = 1} ∩ {S(0) = 0} in Table 1. The effect can then
again be quantified via U1 and U0 introduced in Section 3.2.
Enrico et al. [22] give an overview of the issue of ADAs in the class of immune checkpoint
blockers and re-analyze data of drug trials, by ADA status. They define ADA-positivity
by “patient has ever been ADA+ during the observation period”. However, as discussed
in the previous section, naive analyses defining groups through a post-randomization
event will lead to (i) the comparison of non-comparable population on the treatment
groups and (ii) in this example also to immortal bias (see also e.g. [23, 24, 25, 19] and
the discussion later in Section 4.7). Here, ADA+ patients were not at risk, and thus
“immortal”, of experiencing the outcome event between trial entry and the occurrence of
ADA positivity. How much a causal conclusion based on the analysis in [22] is justified
is thus unclear. In the context of TGI metrics discussed in Section 3.2 this has been
brought up in [26] as well.
3.4 Impact of exposure on OS
The Trastuzumab for Gastric Cancer (ToGA) trial was a 1:1 Phase 3 RCT compar-
ing chemotherapy vs. chemotherapy + trastuzumab in patients with gastric or gastro-
oesophageal junction cancer with over-expression of the HER2 protein [27]. 584 patients
entered the primary analysis. A post hoc exploratory analysis of OS by trastuzumab
exposure in the intervention arm of ToGA was also performed [28], where exposure was
defined as trough minimum concentration, Cmin, at steady state in Cycle 1. Clearly,
Cmin is a post-randomization variable. The authors observed that patients with Cmin
values in the lowest quartile of the Cmin distribution appeared to have shorter OS dura-
tion compared with other quartiles. In order to explore whether other (baseline) factors
than exposure could contribute to the shorter observed OS in the lowest quartile group,
further analyses of baseline patient characteristics by Cmin quartile were performed.
The conclusion was that “...it is unclear whether the lower OS is due to low drug con-
centration or to disease burden.” In a follow-up analysis authors by the FDA in [29]
evaluated the treatment effect in patients in the lowest Cmin quartile (in the chemother-
apy + trastuzumab arm) by appropriately matching these patients with patients in
the chemotherapy only arm, to achieve covariate balance for key baseline covariates.
Although not explicitly described in the potential outcomes framework, this approach
implicitly targets a principal stratum estimand with S being an indicator for Cmin be-
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low a given threshold after Cycle 1 on the test treatment, so that we are again in the
situation of Section 3.2. This analysis together with further exposure-response analyses
based on the ToGA data then triggered initiation of a fully-powered open-label RCT,
HELOISE, that evaluated standard vs. high dose trastuzumab [30], for the identified
subgroup of patients. This case-study illustrates the clinical importance of principal
stratum estimands might have on a drug development program, even if not explicitly
mentioned in the [29] paper.
3.5 Prostate cancer prevention trial
The prostate cancer prevention trial (PCPT, [31]), a double-blind RCT, randomized
18882 men aged 55 years or older to finasteride or placebo. The trial convincingly showed
that men randomized to finasteride had lower rates of prostate cancer. However in [31] it
was noted that among patients who developed prostate cancer after randomization, those
randomized to finasteride had a statistically higher risk of high-grade prostate cancer
compared to those randomized to placebo. The question of interest here is therefore
assessing the effect of finasteride on the severity of prostate cancer among those men
who would be diagnosed with prostate cancer regardless of their treatment assignment,
see [32] for a very nice discussion. Severity was measured using the Gleason score, an
ordered categorical variable that assigned integer values 2-10, with 10 being the most
severe. To make things concrete, Z is the indicator of being randomized to finasteride,
S is the indicator of getting prostate cancer, and Y is the Gleason score.
Interest thus focuses on the distribution functions of the two potential outcomes Y (0)
and Y (1) in the stratum of those patients who get prostate cancer irrespective of treat-
ment assignment, i.e. {S(0) = 1} ∩ {S(1) = 1}. [32] describe how to estimate this
effect and how to statistically test equality of distribution functions of the two potential
outcomes.
In terms of results, naively looking at the distribution of Gleason scores in both arms
suggests that those who got cancer in the finasteride arm had higher Gleason scores.
This naive analysis however did not account for potential post-randomization selection
bias due to differences among treatment arms in patient characteristics of cancer cases
or differential biopsy grading associated with finasteride-induced reductions in prostate
volume [33]. A subsequent sensitivity analysis based on principal stratification [34]
accounting for these two potential sources of selection bias cast doubt on results from
the aforementioned naive analysis. Indeed, a more recent report based on long-term
follow-up of PCPT patients [35] has concluded that The early concerns regarding an
association between finasteride and an increased risk of high-grade prostate cancer have
not been borne out.
3.6 Further examples
Targeting a principal stratum estimand has also been suggested for a variety of further
examples and we sketch and reference some of these below.
An interesting general application of principal stratum is in the context of bioequiva-
lence studies [36, 37]. Traditionally, a per-protocol analysis is performed as a primary
analysis in bioequivalence studies, because the intent-to-treat analysis is not considered
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“conservative”. The intercurrent event S here is protocol adherence, and interest is in
the stratum of patients that would adhere under both treatment and control.
Uemura et al. [38] propose to use principal stratum estimands for assessing quality of
life in face of an intercurrent event that might happen before the assessment of quality
of life. Typically in this case naive analyses are performed that ignore the intercurrent
event.
In the context of schizophrenia, Larsen and Josiassen [39] are interested in the treatment
effect on a continuous outcome Y in patients that would comply if treated with the test
treatment, i.e. the effect in the stratum {S(1) = 1} in Table 1. They propose a new
estimator for this setting.
Akacha et al. [40] suggest the tripartite estimand approach for characterizing the treat-
ment effect in the overall population. They suggest reporting three numbers (i) non-
adherence due to safety (ii) non-adherence due to lack-of-efficacy and (iii) the effect in
adherers. Estimand (iii) corresponds to a principal stratum strategy, see also [41] for a
concrete application of this approach in a diabetes trial.
Principal stratification may also be used to answer relevant questions related to COVID-
19. For example, [42] discuss that estimation of the treatment effect in the principal
stratum of “patients who would never experience severe impact of COVID-19 infection
under either treatment” could be of interest in oncology clinical trials.
There are speculations that vaccines under development for COVID-19 may not prevent
SARS-COV-2 infection, but rather prevent the severity of COVID-19 disease among the
subset of those who will become infected despite vaccination. In the current situation,
even a vaccine-induced dampening of disease severity might be clinically relevant [43].
4 Analysis methods and assumptions
Estimates for principal stratum estimands rely on the validity of additional assumptions.
In the literature, a variety of possible assumptions have been suggested and the choice
of the most appropriate particular set of assumptions will depend on the context of
each specific case. The literature on analysis methods for principal stratum estimands
is vast and an extensive review is beyond the scope of this article. In what follows
we provide a selected overview of commonly utilized assumptions. In addition, we
discuss possible sensitivity analyses in Section 4.6 and considerations specific to principal
stratum estimands for time-to-event endpoints in Section 4.7.
To allow readers to implement some of the analyses presented below, we have developed
a R [6] markdown [44, 45], see Section 6 for the link. The file generates an exemplary
clinical trial data-set containing potential outcomes Y and S as well as a categorical
covariate X mimicking the case study in Section 3.3, and provides explicit code for
some of the analyses described below. Finally, a sensitivity analysis is sketched.
4.1 SUTVA and consistency
Most approaches described rely on the stable unit treatment values assumption (SUTVA),
which entails that (i) the potential outcomes for any patient do not change with the
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treatment assigned to other patients (no interference) and (ii) there are no multiple ver-
sions of treatment. An example where (i) is violated is in the area of infectious diseases:
Depending on the context, whether or not an individual may get infected will depend on
whether other individuals are vaccinated. Part (ii) implies that treatment needs to be
well-defined so that potential outcomes corresponding to a defined treatment are equal
to what is observed in the trial. This is sometimes also called “consistency” assumption
[46]. In addition, most approaches utilize the fact that there is an ignorable treatment
assignment mechanism, as is common in pharmaceutical RCTs.
4.2 Identification bounds
One stream of literature tries to avoid utilizing assumptions. This means that typically
no concrete estimate can be provided but only identification bounds for the parameters
of interest, see for example [47, 48]. The estimation problem then focuses on estimation
of these identification boundaries, for which also confidence intervals can be provided.
Often these bounds might be quite wide and might not provide useful information, but
this depends on the specific data situation. Refinements of boundaries using for example
covariate information were discussed in [49], [50] and [51].
4.3 Monotonicity and exclusion-restriction
Two possible “nonparametric” assumptions to utilize are the monotonicity assumption
and the exclusion-restriction assumption [52]. The monotonicity assumption states that
S(0) ≥ S(1) (or alternatively S(1) ≥ S(0) depending on the situation). This means for
a patient with S(0) = 0 observed we would know that S(1) = 0, so that the bottom-left
stratum in Table 1 would be empty. This assumption allows to estimate the principal
stratum probabilities. The monotonicity assumption may in some situations be scien-
tifically very plausible, but is not verifiable based on observed data. It however implies
that P (S(0) = 1) ≥ P (S(1) = 1), an assumption that can be assessed in a RCT.
The exclusion restriction assumption states that for patients in the strata {S(0) =
0}∩{S(1) = 0} and {S(0) = 1}∩{S(1) = 1} one assumes Y (0) = Y (1), i.e. there would
be no treatment effect in the strata of those experiencing (or not experiencing) the post-
randomization event under either treatment. Formulated alternatively, randomization
has no impact for those subjects for whom treatment has no effect on S [53].
Note that both assumptions make statements on the relationship of potential outcomes
across treatment and control. As potential outcomes across treatment and control are
never observed jointly, these type of assumptions are typically not verifiable and can be
called across-worlds assumptions.
In the context of the multiple sclerosis example of Section 3.1 these assumptions to-
gether would allow identification of the estimand of interest. But while a monotonicity
assumption can well be justified based on earlier data, the exclusion-restriction assump-
tion is not plausible, as the estimand of interest is the treatment effect in the stratum
with no relapses {S(0) = 0} ∩ {S(1) = 0}.
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4.4 Joint models
In [2] a generic likelihood is described for estimation of a principal stratum effect. This
entails a model for the outcome given the principal stratum membership: Y (0), Y (1)|S(1), S(0)
and additionally the principal stratum membership S(0), S(1) itself is modeled. Mul-
tiplying the likelihoods of both models together, implies a joint model for Y and S.
Unobserved potential outcomes are then treated as missing data in [2] and integrated
out to define the likelihood. While covariates are not specifically mentioned, including
them in the model for the principal stratum membership or the outcome is straightfor-
ward. As noted in [2] a unique maximum likelihood estimate generally does not exist
(even asymptotically for “infinite” sample size). Further assumptions are needed, which
typically involve statements on the joint distribution of the potential outcomes across
treatment and control (across-world assumptions).
In a Bayesian setting, prior assumptions on the model parameters can be quantified
in terms of prior distributions and in this case, as long as proper priors are used, also
posterior inference is possible. This idea goes back at least to [54] and was implemented
for estimation in the example in Section 3.1. There a “soft” version of the monotonicity
assumption was used, by specifying an informative prior distribution for the correspond-
ing principal stratum proportion to be close to 0. This allows for sensitivity analyses
through varying the informativeness of the prior distribution. While the model by [14]
in Section 3.1 did not include covariates to model the principal stratum membership,
this is possible (see e.g. [55], [56], [57], [58], [59], [13] in a Bayesian setting).
It is often plausible to assume that covariates might influence principal stratum mem-
bership, so that inference will get more precise. This approach can also be coupled with
additional assumptions like monotonicity and exclusion restriction, which will improve
identification of the underlying inference problem. For example [60], and [61] employ the
exclusion restriction assumption in addition to a parametric assumption in the context
of linear regression, while using the EM-algorithm for ML estimation (extension to a
time-to-event outcome using instrumental variable approaches is discussed in [62] and
[63]). A general challenge, independent of whether a Bayesian or frequentist inference
paradigm is used, is that inference will depend on the parametric assumptions of the
underlying joint models, as well as the covariates used.
In general, when making a parametric assumption on the distribution of the data, the
parameters are identified by the identification of parametric mixture models, and an EM-
type algorithm can be used for statistical inference. Note however that the likelihood
function may display pathological behavior, and standard frequentist inference tools,
like bootstrap cannot be used. For further discussion and references see [64, Section
2.3.2].
4.5 Principal ignorability
The last type of assumption we discuss is conditional independence. In the context of
principal strata this is often called principal ignorability (PI), see [65, 66] for some recent
references. Here, separate models are specified for Y and S, resulting in approaches
that are very similar to propensity score approaches in observational data analyses. For
example, in the early responder example in Section 3.2 the estimand of interest was
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P (Y (1) > t|S(1) = 1)− P (Y (0) > t|S(1) = 1),
where Y was an event time and S early response. Contrary to P (Y (1) > t|S(1) = 1),
estimation of P (Y (0) > t|S(1) = 1) is not straightforward, because Y (0) and S(1) are
not jointly observed in the same patient in a RCT. For patients on treatment that are
biomarker responders, i.e. S = 1, the control outcome Y (0) is unobserved, while for
patients on the control arm the biomarker response status on treatment S(1) is not
observed.
Now, PI states that conditional on baseline covariates (i.e., confounders) X the Y (0)
and S(1) are independent: Y (0) ⊥ S(1)|X, so the covariates X should include those
that explain both Y (0) and S(1) to the extent that they can be considered independent.
This means once the covariates X are known, S(1) provides no further information on
Y (0) and vice versa, i.e., the distributional equality
p(Y (0)|X,S(1)) = p(Y (0)|X)
holds. The benefit from this assumption is that it allows modeling of Y (0) (or S(1))
just based on X, the unobserved outcome does not need to be included in the model.
Based on this, weighting approaches based on propensity scores can e.g. be used as
follows. First, model the probability that S(1) = 1 on the treatment arm depending on
X, e.g. using logistic regression. Then, use the predicted probabilities as weights for
patients on the control arm (see [61, 67] among many others). The same model could
also be used in a multiple imputation approach, i.e. imputing S(1) for patients on the
control arm. An even simpler approach may often be standardization [8]. Depending on
the outcome distribution also plain regression adjustment for X in the outcome model
can be utilized to estimate a principal stratum effect under the PI assumption. Finally,
matching is also feasible. The propensity score literature extensively discusses the pros
and cons of the different analysis techniques, see e.g. [68].
The main assumption of PI is that X contains all variables that potentially confound
Y (0) and S(1) (no unmeasured confounding). As Y (0) and S(1) cannot be jointly
observed, this assumption is hence across-worlds and not verifiable. Its plausibility
needs to be considered on a case-by-case basis.
One practically relevant and important question is how to decide on the covariates X
to use. Here an important point is to adjust for all confounders that make the potential
outcomes of post-randomization event occurrence and the final outcome independent.
So, formally only covariates that confound the two outcomes should be adjusted for,
that is, formally one should not include covariates that help predicting the intercurrent
event but have no impact on the outcome. The discussion on which variables to utilize
is very similar to the discussion in observational data settings, where one tries to find
predictors of both treatment and outcome. A helpful recent overview is provided by
[69], who study the nonparametric setting.
Somewhat similar to principal ignorability is the approach in [39]. For their estimand
described in Section 3.6, they propose an estimator that builds on the fact that the
outcome distribution for patients on the control treatment, is a mixture of compliers
and noncompliers to the test treatment. Exploiting that compliance is fully observed in
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patients on treatment they predict compliance if treated with among patients treated
with control using baseline predictors.
4.6 Sensitivity analyses
Because essentially all analysis strategies targeting principal stratum estimands require
strong assumptions, sensitivity analyses should be performed, depending on how strong
the scientific rationale for the utilized assumptions is. The proposed sensitivity analyses
are often specific to the specific assumptions utilized so that consequently a number
of different sensitivity analyses approaches exist, see for example [65, 70, 71, 72] and
references cited therein. In a Bayesian approach sensitivity analyses are often relatively
straightforward, as for example discussed in [14].
In the setting of bioequivalence trials, [37, 36] were interested in the treatment effect in
the patient that adhere under both treatments. They utilize an idea of [73] to express
the estimand of interest in terms of the naive per-protocol effect with a bias term.
Estimation of the target estimand is then done by the naive per protocol effect and
varying the bias term within reasonable bounds in a tipping point analysis. In addition
they propose to test for equivalence of the proportions of protocol adherence under both
treatments as a co-primary endpoint in bioequivalence studies.
Applying methodology initially proposed in [74], [32] in the PCPT example from Sec-
tion 3.5 apply a sensitivity analysis to assess robustness of the naive analysis that does
not account for potential post-randomization selection bias. They make the distribution
function of the potential outcome in the placebo patients depend on a parameter β that
can be interpreted as follows: given someone got prostate cancer in the placebo arm, for
a one-unit increase in Gleason score, the odds that they would have gotten prostate can-
cer had they been randomized to finasteride arm multiplicatively increases by exp(β).
Plotting the estimated relative effect between the two potential outcomes (or the p-value
as in [32] if interest focuses on hypothesis testing) against this parameter β then allows
an assessment of the dependency of the conclusion on the amount of selection bias.
For assumptions related to principal ignorability tipping point analyses can be used to
assess the sensitivity of assumptions to the underlying conclusions. Here Y (0) or S(1)
would be used as potential predictor of S(1) or Y (0) on top of X. As the effect of Y (0)
on S(1) or the effect of S(1) on Y (0) cannot be estimated based on data, these effects
would need to be varied in a sensitivity analysis. Another important sensitivity analysis
related to principal ignorability is to vary the set of confounders X utilized.
4.7 Special considerations for time-to-event endpoints
As discussed earlier time-to-event endpoints require special considerations, as the pri-
mary event in some situations might be a competing risk to observing the intercurrent
event status, potentially leading to immortal bias when utilizing naive analyses. If the
primary event is death this is obvious, but this situation might also occur for example
when the primary event triggers a stop of the treatment and the intercurrent event can
only happen while on treatment. Then intercurrent event cannot be observed after stop
of treatment.
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Assume we are interested in the subpopulation with S(1) = 1 and the outcome Y is of
time-to-event type, further let TS(1) be the potential event time for occurrence of S(1).
Then in the situation described above the event S(1) = 1 implies TS(1) < Y (1), so that
implicitly the stratum of interest would be {S(1) = 1} ∩ {TS(1) < Y (1)}.
When the intercurrent event status S(1) is observed for every unit at a fixed time t˜, the
occurrence of the primary event Y before t˜ would make observation of S(1) impossible so
that observation of S(1) implies Y (1) > t˜. The stratum S(1) = 1 would then implicitly
be defined as {S(1) = 1} ∩ {Y (1) > t˜}.
In both situations the stratum is no longer only described by S(1), but also by Y (1). As
the main comparison of interest is between Y (0) and Y (1) and the principal stratum itself
is now also defined in terms of the observed outcome Y (1), it becomes more challenging
to find realistic assumptions that would allow estimation of principal stratum effects.
When interest focuses on {S(1) = 1} ∩ {Y (1) > t˜} it is easier to find plausible assump-
tions when t˜ is “small”, that is, very few events Y are expected before time t˜. This could
for example be fulfilled in the early responder, exposure, or ADA example in Sections
3.2, 3.3, 3.4, when the intercurrent event status can be identified early. Depending on
the specific situation (e.g., if Y measures non-fatal events), in the three examples above
it might also be possible to assess S(1) even after the event Y (1) has already happened,
so that one would not necessarily be in the situation discussed in this section, where the
event and intercurrent events are competing risks.
This problem is also discussed in some detail in [75] in the context of treatment switching,
where the event (death in their considered case) is a competing risk to treatment switch.
5 Discussion
We believe that there are a number of relevant questions in drug development that can be
formulated as principal stratum estimands. These are often not related to the primary
objective of the trial, but can still play an important role to characterize how the drug
works in relevant subpopulations defined by different post-randomization events.
That these type of questions are relevant for Health Authorities from a clinical per-
spective can e.g. be inferred from the anticancer guidance issued by the European
Medicines Agency [76]. This guidance has a dedicated section (7.6.5) on “Analyses
based on a grouping of patients on an outcome of treatment”, illustrating the regula-
tory interest in these kind of questions. The MS example discussed in Section 3.1 is
also available as Public Assessment Report of the European Medicines Agency [77]. In
addition, of course, the ICH E9(R1) estimand working group considered the principal
stratum strategy as important enough to list it as one of the five intercurrent event
strategies.
Questions about the impact of clinical events such as exposure, response, or safety events
like ADA on the outcome of interest have always been relevant in drug development.
However, although often criticized in the literature, simple analyses such as comparing
subgroups based on a post-randomization event are not uncommon in an attempt to an-
swer such questions. Causal effects were, at least implicitly, claimed from such analysis.
Even though the formal idea of principal stratum estimands had been proposed in the
causal inference literature two decades ago, the explicit uptake of these methods in the
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drug development community has so far been low. While there are examples of analyses
that appropriately would target principal stratum estimands (for example [29]), explicit
use of principal stratum estimands has been limited. Exceptions exist, e.g. to assess
efficacy on a post-infection endpoint in a vaccine trial in [78]. We believe and hope
this will change with the principal stratum approach being prominently mentioned as a
strategy in the ICH E9(R1) guideline. The advantage of adopting the principal stratum
strategy for these questions is that it provides a clear inferential target. Having an
inferential target is crucial to assess the adequacy of assumptions or specific analyses.
Even more generally, in our experience approaching traditional analyses with a potential
outcome mindset often allows to make implicit assumptions of traditional analyses more
transparent, as in the example discussed in Section 2.
The type of assumptions typically required for identification of principal stratum es-
timands are quite strong and usually unverifiable. While similar type of unverifiable
assumptions have long been used in drug development, for example missing-at-random
or independent censoring assumptions, the impact might be stronger here as assump-
tions are not only used to “impute” missing responses for a potentially small subset of
the overall trial population, but depending on the data situation and the type of as-
sumption might drive inference. However, availability of a clear inferential target though
based on unverifiable assumptions has to be traded off against “naive” analyses whose
causal interpretation is unclear, if not to say invalid.
We think that (i) utilized assumptions need to be motivated by clinical or scientific
insights and (ii) that sensitivity analyses need to be performed for any analysis targeting
a principal stratum estimand. While sensitivity analyses for certain assumptions, e.g.
monotonicity, have been proposed in the literature and we tried to review some ideas
for further sensitivity analyses in this paper, we believe there is a need for further
developments and practical guidance in this area.
6 Data Availability Statement
The markdown file discussed in Section 4 is available as a github repository: https://
github.com/oncoestimand/princ_strat_drug_dev.git. The direct link to the mark-
down file is: https://oncoestimand.github.io/princ_strat_drug_dev/princ_strat_
example.html.w
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